Montanide ISA-51 VG
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Montanide ISA-51 VG, covering 2014-04-30 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer [Phase 1, Phase 2]